is a highly complex disease and it turned out over the
past decades that it is difficult to develop efficient
and sustainable therapies or even cure the disease. The
difficulty in finding sustainable therapies or even a
cure for cancer lies in the heterogeneity of cancer
diseases: Tumors consist of different cell types, tumor
cells are genetically variable and even the same cancer
type differs from patient to patient. Therefore, key to
combat this complex disease lies in finding optimal
combinations of cancer drugs in test systems that best
represent the complexity and heterogeneity of cancer.
Next generation combinatorial drug discovery
anti-cancer drug combinations are either developed
directly by treating patients combining drugs which are
already on the market or using ex vivo screening models.
Screening models which are currently used do either not
reflect the heterogeneity of native tumors or are not
high throughput compatible. To overcome the limitations
of traditional drug screening, PreComb has developed a
unique drug screening technology that optimally
represents the complexity of patient's disease in a
format that allows for automated high-throughput testing
of thousands of drug combinations. Using clinically
relevant readouts, results from drug testing can be
directly translated to therapeutic application in
patients. This novel screening approach is capable of
identifying drug combinations with additive or
synergistic long-term therapeutic effects for the
ultimate goal to improve the patients survival and
quality of life.
the highly standardized setup of the screening
technology, PreComb is approaching all major drug
modalities to be combined: small molecules, biologics
and immune-modulatory agents.
offers its unique discovery platform capabilities to
partners seeking to make better use of their drugs by
new combinations, to better exploit existing compound
libraries or to find new drug combinations that have a
sustainable therapeutic effect in a broader patient
population. For further discussions on development
collaborations, please contact firstname.lastname@example.org.